Litcius/Paper detail

Etomidate elicits anti-tumor capacity by disrupting the JAK2/STAT3 signaling pathway in hepatocellular carcinoma

Jiali Xu, Liren Zhang, Nana Li, Jingjing Dai, Ruizhi Zhang, Feifan Yao, Suiqing Zhou, Zifeng Wu, Huixuan Zhou, Ling Zhou, Qing Li, Xuehao Wang, Cunming Liu

2022Cancer Letters25 citationsDOI

Topics & Concepts

EtomidateMedicineHepatocellular carcinomaMalignancyAnesthetic AgentCancer researchAnestheticPharmacologyInternal medicineAnesthesiaPropofolCancer, Stress, Anesthesia, and Immune ResponseEicosanoids and Hypertension PharmacologyCancer, Hypoxia, and Metabolism
Etomidate elicits anti-tumor capacity by disrupting the JAK2/STAT3 signaling pathway in hepatocellular carcinoma | Litcius